

Market insights summary

United States neurostimulation device market

What's trending and new

01. Companies are focused on innovating their devices to enhance adoption & treatment outcomes

- Companies like Medtronic, Boston Scientific, and Abbott Laboratories are developing neurostimulation devices with enhanced target specificity, physiological response sensing, and adjustable stimulation frequencies for personalized treatment.
- Competitors in multiple device segments are pursuing U.S. Food & Drug Administration approval for new indications, which will enable treatment of new patient populations and ultimately drive unit sales.

02. Neurostimulation effectiveness has the potential to be markedly increased by closed-loop devices

- Closed-loop devices are intended to adjust stimulation in real-time based on patients' physiological responses.
- Saluda Medical's Evoke System does this for chronic pain, while Medtronic has technologies in deep brain stimulation (DBS) and spinal cord stimulation (SCS).

03. Increasing adoption of hypoglossal nerve stimulation (HGNS) devices

- The HGNS device market continues to grow at a rapid pace, driven by expanding reimbursement efforts led by Inspire Medical Systems, currently the sole player in the HGNS device market.
- LivaNova's aura6000 HGNS device will boost volumes after its U.S. launch, and Nyxoah is evaluating HGNS for obstructive sleep apnea patients with soft palate collapse.

Access more insights and data in the [report](#).
[Speak to our team](#) to see how we can power your innovation.

2023 U.S. neurostimulation device market snapshot


\$4.38B

Market revenue

7.1%


CAGR ('19-'33)

U.S. neurostimulation device market, by product type, USD B




GES: gastric electric stimulation; HGNS: hypoglossal nerve stimulation; TNS: tibial nerve stimulation; VNS: vagus nerve stimulation; SNS: sacral nerve stimulation; DBS: deep brain stimulation, SCS: spinal cord stimulation

Proportion of neurostimulation devices by procedure type, 2023



2023 US competitive landscape



Medtronic

- Medtronic continues to lead various neurostimulation device segments but has recently faced strong competition in the SCS, DBS, and SNS device markets.

Boston Scientific

- Despite competing in fewer segments than Medtronic in 2023, Boston Scientific has become a leading player in the SCS and DBS device markets by focusing on innovation and novel technologies.